Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.
The mechanisms of human papillomavirus (HPV) neutralization by antibodies are incompletely understood. We have used HPV16 pseudovirus infection of HaCaT cells to analyze how several neutralizing monoclonal antibodies (MAbs) generated against HPV16 L1 interfere with the process of keratinocyte infection. HPV16 capsids normally bind to both the cell surface and extracellular matrix (ECM) of HaCaT cells. Surprisingly, two strongly neutralizing MAbs, V5 and E70, did not prevent attachment of capsids to the cell surface. However, they did block association with the ECM and prevented internalization of cell surface-bound capsids. In contrast, MAb U4 prevented binding to the cell surface but not to the ECM. The epitope recognized by U4 was inaccessible when virions were bound to the cell surface but became accessible after endocytosis, presumably coinciding with receptor detachment. Treatment of capsids with heparin, which is known to interfere with binding to cell surface heparan sulfate proteoglycans (HSPGs), also resulted in HPV16 localization to the ECM. These results suggest that the U4 epitope on the intercapsomeric C-terminal arm is likely to encompass the critical HSPG interaction residues for HPV16, while the V5 and E70 epitopes at the apex of the capsomer overlap the ECM-binding sites. We conclude that neutralizing antibodies can inhibit HPV infection by multiple distinct mechanisms, and understanding these mechanisms can add insight to the HPV entry processes.
Day
Patricia M
PM
Laboratory of Cellular Oncology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA. pmd@nih.gov
Thompson
Cynthia D
CD
Buck
Christopher B
CB
Pang
Yuk-Ying S
YY
Lowy
Douglas R
DR
Schiller
John T
JT
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000914:Antibodies, Viral / Q000494:pharmacology*; D002213:Capsid / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism / Q000821:virology*; D000939:Epitopes / Q000276:immunology; D005109:Extracellular Matrix / Q000378:metabolism / Q000821:virology*; D019812:Heparan Sulfate Proteoglycans / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology; D052162:Human papillomavirus 16 / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D015603:Keratinocytes / Q000821:virology; D009500:Neutralization Tests; D014771:Virion / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000939:Epitopes; D019812:Heparan Sulfate Proteoglycans; D006493:Heparin